Cargando…

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives

Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved me...

Descripción completa

Detalles Bibliográficos
Autores principales: Barba Bernal, Romelia, Ferrigno, Bryan, Medina Morales, Esli, Castro, Cristina M., Goyes, Daniela, Trivedi, Hirsh, Patwardhan, Vilas R., Bonder, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Gastroenterology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081121/
https://www.ncbi.nlm.nih.gov/pubmed/36843300
http://dx.doi.org/10.5152/tjg.2023.22239
_version_ 1785021051277672448
author Barba Bernal, Romelia
Ferrigno, Bryan
Medina Morales, Esli
Castro, Cristina M.
Goyes, Daniela
Trivedi, Hirsh
Patwardhan, Vilas R.
Bonder, Alan
author_facet Barba Bernal, Romelia
Ferrigno, Bryan
Medina Morales, Esli
Castro, Cristina M.
Goyes, Daniela
Trivedi, Hirsh
Patwardhan, Vilas R.
Bonder, Alan
author_sort Barba Bernal, Romelia
collection PubMed
description Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets.
format Online
Article
Text
id pubmed-10081121
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Turkish Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-100811212023-04-08 Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives Barba Bernal, Romelia Ferrigno, Bryan Medina Morales, Esli Castro, Cristina M. Goyes, Daniela Trivedi, Hirsh Patwardhan, Vilas R. Bonder, Alan Turk J Gastroenterol Review Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets. Turkish Society of Gastroenterology 2023-02-01 /pmc/articles/PMC10081121/ /pubmed/36843300 http://dx.doi.org/10.5152/tjg.2023.22239 Text en 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Barba Bernal, Romelia
Ferrigno, Bryan
Medina Morales, Esli
Castro, Cristina M.
Goyes, Daniela
Trivedi, Hirsh
Patwardhan, Vilas R.
Bonder, Alan
Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title_full Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title_fullStr Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title_full_unstemmed Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title_short Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
title_sort management of primary biliary cholangitis: current treatment and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081121/
https://www.ncbi.nlm.nih.gov/pubmed/36843300
http://dx.doi.org/10.5152/tjg.2023.22239
work_keys_str_mv AT barbabernalromelia managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT ferrignobryan managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT medinamoralesesli managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT castrocristinam managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT goyesdaniela managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT trivedihirsh managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT patwardhanvilasr managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives
AT bonderalan managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives